These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26638929)

  • 1. Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease.
    Sinha R; Lockman KA
    Aliment Pharmacol Ther; 2016 Jan; 43(1):163. PubMed ID: 26638929
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
    Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
    Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.
    Kwok R; Choi KC; Wong GL; Zhang Y; Chan HL; Luk AO; Shu SS; Chan AW; Yeung MW; Chan JC; Kong AP; Wong VW
    Gut; 2016 Aug; 65(8):1359-68. PubMed ID: 25873639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors.
    Prasetya IB; Hasan I; Wisnu W; Rumende CM
    Acta Med Indones; 2017 Apr; 49(2):91-98. PubMed ID: 28790222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease and the interface between primary and secondary care.
    Tsochatzis EA; Newsome PN
    Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):509-517. PubMed ID: 29893235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.
    Lonardo A; Ballestri S; Guaraldi G; Nascimbeni F; Romagnoli D; Zona S; Targher G
    World J Gastroenterol; 2016 Nov; 22(44):9674-9693. PubMed ID: 27956792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.
    Noureddin M; Jones C; Alkhouri N; Gomez EV; Dieterich DT; Rinella ME;
    Gastroenterology; 2020 Nov; 159(5):1985-1987.e4. PubMed ID: 32763241
    [No Abstract]   [Full Text] [Related]  

  • 10. [Epidemiology of non-alcoholic steatohepatitis. Extent/burden of the problem and its impact on public health].
    Vallet-Pichard A; Parlati L; Pol S
    Presse Med; 2019 Dec; 48(12):1459-1467. PubMed ID: 31757728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
    Zhu C; Zhou D; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing liver fibrosis in patients with NAFLD and the road ahead.
    Nobili V; Miele L; Alisi A
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1081-1083. PubMed ID: 28994314
    [No Abstract]   [Full Text] [Related]  

  • 14. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
    Margini C; Dufour JF
    Liver Int; 2016 Mar; 36(3):317-24. PubMed ID: 26601627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
    Tilg H
    Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
    [No Abstract]   [Full Text] [Related]  

  • 16. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas.
    Shoreibah M; Raff E; Bloomer J; Kakati D; Rasheed K; Kuo YF; Singal AK
    Ann Hepatol; 2016; 15(2):183-9. PubMed ID: 26845595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
    Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
    Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.